Lindsey C. Bohl

Lindsey Bohl is a Partner in Simpson Thacher’s Washington, D.C. office. She advises on matters involving all aspects of antitrust and competition law, including merger reviews, government antitrust investigations and antitrust litigation. Her practice focuses on counseling clients considering M&A transactions across a wide range of industries, including healthcare, retail, consumer products, technology and medical devices and pharmaceutical products. Lindsey’s extensive merger clearance experience includes numerous significant recent merger challenges, including representing Amedisys in its settlement with DOJ resolving claims relating to its proposed acquisition by United Healthcare, and prevailing over the FTC in court in Tempur Sealy/Mattress Firm. Lindsey also regularly advises clients on the evolving and complex landscape of state healthcare premerger notification requirements.

Lindsey was recently named a Law360 Rising Star in Competition Law for 2026, a National Law Journal Rising Star – Antitrust for 2026, and as a finalist in Global Competition Review’s GCR Awards 2026 for “Lawyer of the Year (Under 40).” In addition, she is a recognized thought leader on antitrust-related topics and frequently speaks at industry conferences including those sponsored by the American Bar Association (ABA), American Health Law Association (AHLA), and other private organizations.

Her recent work highlights include advising on the antitrust aspects of numerous transactions, including: 

• Amedisys in its $3.3 billion sale to UnitedHealth, following a negotiated settlement with the Department of Justice;

• Mattress Firm in its $5 billion acquisition by Tempur Sealy, including successful litigation against the FTC;

• BrightSpring Health in the pending sale of its ResCare Community Living business to Sevita;

• HCA Healthcare in its purchase of 40 urgent care centers from Community Care Partners;

• HCA Healthcare in securing COPA approval of its sale of Terre Haute Regional Hospital to Union Health, following FTC opposition;

• HCA Healthcare in its acquisition of Wise Health System and in its sale of West Hills Medical Center to UCLA Health;

• G-III Apparel Group in its acquisition of the remaining 81% interest in fashion brand Karl Lagerfeld;

• Vyaire in the sale of its respiratory consumables business to SunMed;

• BMW and Daimler’s formation of a mobility services joint venture, including coordination of responses to Second Requests issued to both parties;

• Siliconware Precision Industries in securing antitrust clearance, following an FTC investigation, of its merger with Taiwanese competitor Advanced Semiconductor Engineering;

• Garda World Security Corporation in its acquisitions of Whelan Security, OnSolve and Stealth Monitoring;

• Vistra Energy, the parent company for TXU Energy and Luminant, in its combination with Dynegy;

• Acelity, a portfolio company of Apax Partners, CPP and PSP, in its sale of its LifeCell Business Unit to Allergan for $2.9 billion;

• Ahold N.V. in its $29 billion merger of equals with Delhaize Group; and

• Lorillard in its $27.4 billion sale to Reynolds American.

Before rejoining Simpson Thacher, where she began her career as an associate, Lindsey was a staff attorney in the FTC’s Mergers IV Division, where she led significant healthcare and retail transaction investigations and litigated merger challenges, including the FTC’s successful lawsuit challenging Hackensack Meridian Health’s acquisition of Englewood Health in New Jersey. She earned her J.D., cum laude, from Georgetown University Law Center and her B.A., magna cum laude, from Vanderbilt University. She is admitted to practice in Washington, D.C. and New York.